Kura Oncology
2014
FOUNDED
PUBLIC
STATUS
41-50
EMPLOYEES
KURA
STOCK SYMBOL
1
INVESTMENTS
$20.32
SHARE PRICE
(As of Tuesday Closing)
Description
Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through United States.
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
- 11119 North Torrey Pines Road
- Suite 125, La Jolla
- San Diego, CA 92037
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Kura Oncology’s full profile, request a free trial.
Kura Oncology Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $10.20 - $22.00 | $776M | $20.33 | -$1.64 | 334K | 38.2M |
Kura Oncology Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 461,739 | 352,882 | 368,535 | 58,810 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (62,670) | (62,636) | (35,267) | (27,451) |
| Net Income | (59,783) | (60,447) | (35,434) | (27,560) |
| Total Assets | 169,617 | 182,379 | 95,851 | 69,821 |
| Total Debt | 7,500 | 7,500 | 7,098 | 7,324 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kura Oncology Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Kura Oncology‘s full profile, request access.
Request full access to PitchBookKura Oncology Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 00000000000 | 06-Mar-2015 | 000000000000000000 | Holding Companies |
Kura Oncology Executive Team (8)
1 Former Executive
You’re viewing 5 of 8 executives. Get the full list »